Global Anti-Obesity Drugs Market By Type (Prescription Drugs , and OTC drugs), By Application (6-18 Callant , 18-30 Adult , and 30-60Middle-Aged), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029
- account_circleAbout Me
- 55148
-
US $6,000US $3,999
-
US $8,000US $5,999
-
US $10,000US $6,999
Global Anti-Obesity Drugs Market is estimated to be valued US$ XX.X million in 2019. The report on Anti-Obesity Drugs Market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, etc. for the forecast year up to 2029. The global anti-obesity drugs market is segmented on the basis of type, application, and geography.
In 2019, the North America market is valued US$ XX.X million and the market share is estimated X.X%, and it is expected to be US$ XX.X million and X.X% in 2029, with a CAGR X.X% from 2020 to 2029.
Anti-Obesity Drugs Market Scope:
By type, the market is segmented into Prescription Drugs, and OTC drugs. By application, the market is divided into 6-18 Callant, 18-30 Adult, and 30-60Middle-Aged.
Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Pfizer, Merck, F.Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Eisai, Norgine, Arena Pharmaceuticals, Orexigen Therapeutics, Vivus, Alizyme, Rhythm Pharmaceuticals, Shionogi, and Zafgan.
Key Market Segments
Type
- Prescription Drugs
- OTC drugs
Application
- 6-18 Callant
- 18-30 Adult
- 30-60Middle-Aged
Key Market Players included in the report:
- Pfizer
- Merck
- F.Hoffmann-La Roche
- GlaxoSmithKline
- AstraZeneca
- Boehringer Ingelheim
- Novo Nordisk
- Eisai
- Norgine
- Arena Pharmaceuticals
- Orexigen Therapeutics
- Vivus
- Alizyme
- Rhythm Pharmaceuticals
- Shionogi
- Zafgan
Reasons to Get this Report:
In an insight outlook, this research report has dedicated to several quantities of analysis - industry research (global industry trends) and Anti-Obesity Drugs Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Anti-Obesity Drugs Market; high-growth regions; and market drivers, restraints, and also market chances.
The analysis covers Anti-Obesity Drugs Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Anti-Obesity Drugs Market across sections such as also application and representatives.
Additionally, the analysis also has a comprehensive review of the crucial players on the Anti-Obesity Drugs Market together side their company profiles, SWOT analysis, latest advancements, and business plans.
The analysis objectives of the report are:
- To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
- To know the Anti-Obesity Drugs Market by pinpointing its many subsegments.
- To profile the important players and analyze their growth plans.
- To endeavor the amount and value of Anti-Obesity Drugs sub-markets, depending on key regions (various vital states).
- To analyze Anti-Obesity Drugs Market concerning growth trends, prospects, and also their participation in the entire sector.
- To examine and study the Anti-Obesity Drugs Market size (volume & value) from the company, essential regions/countries, products, and application, background information from 2013 to 2018, and also prediction to 2029.
- Primary worldwide Anti-Obesity Drugs Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
- To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.
For the Anti-Obesity Drugs Market research study, the following years have been considered to estimate the market size:
Particular Scope Region - North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Historic Year 2016 to 2020 Base Year 2021 Estimated Year 2022 Forecast Year 2023 to 2032 - account_circleAbout Me
- 55148
-
US $6,000US $3,999
-
US $8,000US $5,999
-
US $10,000US $6,999
- 1. Anti-Obesity Drugs Market Introduction
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 2. Executive Summary
- 2.1. Key Findings by Major Segments
- 2.2. Top strategies by Major Players
- 3. Global Anti-Obesity Drugs Market Overview
- 3.1. Anti-Obesity Drugs Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Opportunities
- 3.1.3. Restraints
- 3.1.4. Challenges
- 3.2. PESTLE Analysis
- 3.3. Opportunity Map Analysis
- 3.4. PORTER'S Five Forces Analysis
- 3.5. Market Competition Scenario Analysis
- 3.6. Product Life Cycle Analysis
- 3.7. Opportunity Orbits
- 3.8. Production Analysis by Region/Company
- 3.9. Industry chain Analysis
- 3.10. Marketing Strategy
- 3.1. Anti-Obesity Drugs Market Dynamics
- 4. Global Anti-Obesity Drugs Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
- 4.1. Global Anti-Obesity Drugs Market Analysis by Type: Introduction
- 4.2. Market Size and Forecast by Region
- 4.3. Prescription Drugs
- 4.4. OTC drugs
- 5. Global Anti-Obesity Drugs Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
- 5.1. Global Anti-Obesity Drugs Market Analysis by Application: Introduction
- 5.2. Market Size and Forecast by Region
- 5.3. 6-18 Callant
- 5.4. 18-30 Adult
- 5.5. 30-60Middle-Aged
- 6. Global Anti-Obesity Drugs Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
- 6.1. North America
- 6.1.1. North America Anti-Obesity Drugs Market: Regional Trend Analysis
- 6.1.1.1. US
- 6.1.1.2. Canada
- 6.1.1.3. Mexico
- 6.1.1. North America Anti-Obesity Drugs Market: Regional Trend Analysis
- 6.2.1. Europe
- 6.2.1. Europe Anti-Obesity Drugs Market: Regional Trend Analysis
- 6.2.1.1. Germany
- 6.2.1.2. France
- 6.2.1.3. UK
- 6.2.1.4. Russia
- 6.2.1.5. Italy
- 6.2.1.6. Spain
- 6.2.1.7. Rest of Europe
- 6.2.1. Europe Anti-Obesity Drugs Market: Regional Trend Analysis
- 6.3. Asia-Pacific
- 6.3.1. Asia-Pacific Anti-Obesity Drugs Market: Regional Trend Analysis
- 6.3.1.1. China
- 6.3.1.2. Japan
- 6.3.1.3. Korea
- 6.3.1.4. India
- 6.3.1.5. Rest of Asia-Pacific
- 6.3.1. Asia-Pacific Anti-Obesity Drugs Market: Regional Trend Analysis
- 6.4. Latin America
- 6.4.1. Latin America Anti-Obesity Drugs Market: Regional Trend Analysis
- 6.4.1.1. Brazil
- 6.4.1.2. Argentina
- 6.4.1.3. Rest of Latin America
- 6.4.1. Latin America Anti-Obesity Drugs Market: Regional Trend Analysis
- 6.5. Middle East and Africa
- 6.5.1. Middle East and Africa Anti-Obesity Drugs Market: Regional Trend Analysis
- 6.5.1.1. GCC
- 6.5.1.2. South Africa
- 6.5.1.3. Israel
- 6.5.1.4. Rest of MEA
- 6.5.1. Middle East and Africa Anti-Obesity Drugs Market: Regional Trend Analysis
- 6.1. North America
- 7. Global Anti-Obesity Drugs Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 7.1. Market Share Analysis
- 7.2. Company Profiles
- 7.3. Pfizer
- 7.3.1. Company Overview
- 7.3.2. Financial Highlights
- 7.3.3. Product Portfolio
- 7.3.4. SWOT Analysis
- 7.3.5. Key Strategies and Developments
- 7.4. Merck
- 7.4.1. Company Overview
- 7.4.2. Financial Highlights
- 7.4.3. Product Portfolio
- 7.4.4. SWOT Analysis
- 7.4.5. Key Strategies and Developments
- 7.5. F.Hoffmann-La Roche
- 7.5.1. Company Overview
- 7.5.2. Financial Highlights
- 7.5.3. Product Portfolio
- 7.5.4. SWOT Analysis
- 7.5.5. Key Strategies and Developments
- 7.6. GlaxoSmithKline
- 7.6.1. Company Overview
- 7.6.2. Financial Highlights
- 7.6.3. Product Portfolio
- 7.6.4. SWOT Analysis
- 7.6.5. Key Strategies and Developments
- 7.7. AstraZeneca
- 7.7.1. Company Overview
- 7.7.2. Financial Highlights
- 7.7.3. Product Portfolio
- 7.7.4. SWOT Analysis
- 7.7.5. Key Strategies and Developments
- 7.8. Boehringer Ingelheim
- 7.8.1. Company Overview
- 7.8.2. Financial Highlights
- 7.8.3. Product Portfolio
- 7.8.4. SWOT Analysis
- 7.8.5. Key Strategies and Developments
- 7.9. Novo Nordisk
- 7.9.1. Company Overview
- 7.9.2. Financial Highlights
- 7.9.3. Product Portfolio
- 7.9.4. SWOT Analysis
- 7.9.5. Key Strategies and Developments
- 7.10. Eisai
- 7.10.1. Company Overview
- 7.10.2. Financial Highlights
- 7.10.3. Product Portfolio
- 7.10.4. SWOT Analysis
- 7.10.5. Key Strategies and Developments
- 7.11. Norgine
- 7.11.1. Company Overview
- 7.11.2. Financial Highlights
- 7.11.3. Product Portfolio
- 7.11.4. SWOT Analysis
- 7.11.5. Key Strategies and Developments
- 7.12. Arena Pharmaceuticals
- 7.12.1. Company Overview
- 7.12.2. Financial Highlights
- 7.12.3. Product Portfolio
- 7.12.4. SWOT Analysis
- 7.12.5. Key Strategies and Developments
- 7.13. Orexigen Therapeutics
- 7.13.1. Company Overview
- 7.13.2. Financial Highlights
- 7.13.3. Product Portfolio
- 7.13.4. SWOT Analysis
- 7.13.5. Key Strategies and Developments
- 7.14. Vivus
- 7.14.1. Company Overview
- 7.14.2. Financial Highlights
- 7.14.3. Product Portfolio
- 7.14.4. SWOT Analysis
- 7.14.5. Key Strategies and Developments
- 7.15. Alizyme
- 7.15.1. Company Overview
- 7.15.2. Financial Highlights
- 7.15.3. Product Portfolio
- 7.15.4. SWOT Analysis
- 7.15.5. Key Strategies and Developments
- 7.16. Rhythm Pharmaceuticals
- 7.16.1. Company Overview
- 7.16.2. Financial Highlights
- 7.16.3. Product Portfolio
- 7.16.4. SWOT Analysis
- 7.16.5. Key Strategies and Developments
- 7.17. Shionogi
- 7.17.1. Company Overview
- 7.17.2. Financial Highlights
- 7.17.3. Product Portfolio
- 7.17.4. SWOT Analysis
- 7.17.5. Key Strategies and Developments
- 7.18. Zafgan
- 7.18.1. Company Overview
- 7.18.2. Financial Highlights
- 7.18.3. Product Portfolio
- 7.18.4. SWOT Analysis
- 7.18.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- ondemand_videoVideos
- 55148
-
US $6,000US $3,999
-
US $8,000US $5,999
-
US $10,000US $6,999
- Pfizer
- Merck
- F.Hoffmann-La Roche
- GlaxoSmithKline
- AstraZeneca
- Boehringer Ingelheim
- Novo Nordisk
- Eisai
- Norgine
- Arena Pharmaceuticals
- Orexigen Therapeutics
- Vivus
- Alizyme
- Rhythm Pharmaceuticals
- Shionogi
- Zafgan
- settingsSettings